Suppr超能文献

2019冠状病毒病的严重程度及糖尿病患者的治疗策略

Severity of COVID-19 and Treatment Strategy for Patient With Diabetes.

作者信息

Jin Shi, Hu Weina

机构信息

Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.

Department of Cardiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.

出版信息

Front Endocrinol (Lausanne). 2021 Apr 30;12:602735. doi: 10.3389/fendo.2021.602735. eCollection 2021.

Abstract

Coronavirus disease 2019 (COVID-19), which was named by the World Health Organization (WHO) in February 2020, has quickly spread to more than 200 countries around the world and was declared as a global pandemic in March 2020. The severity of the disease makes it more prone to severe symptoms and higher mortality rates in patients, especially those who are with comorbidities, including high blood pressure, cardiovascular disease, obesity, and diabetes, increases the concern over the consequences of this pandemic. However, initial reports do not clearly describe whether diabetes itself or associated comorbidities or treatment strategies contribute to the severe prognosis of COVID-19 infections. Various clinical trials are being conducted on glucose-lowering agents but to date, there is no standard treatment protocol approved for COVID-19 cases with pre-existing diabetes. This review is aimed to decipher the potential risk factors of COVID-19 involved from existing evidence. Identification of a novel therapeutic strategy could be beneficial for combating SARS-CoV-2, which might be dreadful to debilitating people who have diabetes.

摘要

2019冠状病毒病(COVID-19)于2020年2月由世界卫生组织(WHO)命名,迅速蔓延至全球200多个国家,并于2020年3月被宣布为全球大流行。该疾病的严重性使其在患者中更容易出现严重症状和更高的死亡率,尤其是那些患有包括高血压、心血管疾病、肥胖症和糖尿病在内的合并症的患者,这增加了人们对这场大流行后果的担忧。然而,初步报告并未明确描述是糖尿病本身、相关合并症还是治疗策略导致了COVID-19感染的严重预后。目前正在对降糖药物进行各种临床试验,但迄今为止,尚无针对已有糖尿病的COVID-19病例批准的标准治疗方案。本综述旨在从现有证据中解读COVID-19的潜在风险因素。确定一种新的治疗策略可能有助于对抗严重急性呼吸综合征冠状病毒2(SARS-CoV-2),这对患有糖尿病的虚弱人群可能是可怕的。

相似文献

1
Severity of COVID-19 and Treatment Strategy for Patient With Diabetes.
Front Endocrinol (Lausanne). 2021 Apr 30;12:602735. doi: 10.3389/fendo.2021.602735. eCollection 2021.
3
Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis.
Diabetologia. 2021 Jul;64(7):1480-1491. doi: 10.1007/s00125-021-05458-8. Epub 2021 Apr 28.
4
Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19).
Diabetes Metab Res Rev. 2021 Feb;37(2):e3377. doi: 10.1002/dmrr.3377. Epub 2020 Jul 20.
7
Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review.
Diabetes Res Clin Pract. 2020 Jul;165:108266. doi: 10.1016/j.diabres.2020.108266. Epub 2020 Jun 11.
8
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review.
Front Endocrinol (Lausanne). 2021 Mar 31;12:609470. doi: 10.3389/fendo.2021.609470. eCollection 2021.
9
The Centrality of Obesity in the Course of Severe COVID-19.
Front Endocrinol (Lausanne). 2021 Mar 11;12:620566. doi: 10.3389/fendo.2021.620566. eCollection 2021.
10
Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.
Eur J Pharmacol. 2020 Sep 5;882:173329. doi: 10.1016/j.ejphar.2020.173329. Epub 2020 Jun 30.

引用本文的文献

3
Characteristics of lymphocyte subsets and cytokine profiles of patients with COVID-19.
Virol J. 2022 Mar 28;19(1):57. doi: 10.1186/s12985-022-01786-2.
4
Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India.
Eur Arch Otorhinolaryngol. 2022 Jun;279(6):3201-3210. doi: 10.1007/s00405-022-07282-1. Epub 2022 Feb 5.
5
Enhanced endocytosis elevated virulence and severity of SARS-CoV-2 due to hyperglycemia in type 2 diabetic patients.
Gene Rep. 2022 Mar;26:101495. doi: 10.1016/j.genrep.2022.101495. Epub 2022 Jan 14.
6
The underlying mechanisms for severe COVID-19 progression in people with diabetes mellitus: a critical review.
AIMS Public Health. 2021 Oct 26;8(4):720-742. doi: 10.3934/publichealth.2021057. eCollection 2021.

本文引用的文献

2
Glycemic fluctuations caused by COVID-19: Results from continuous glucose monitoring.
Obes Med. 2021 Mar;22:100328. doi: 10.1016/j.obmed.2021.100328. Epub 2021 Feb 16.
3
From Influenza Virus to Novel Corona Virus (SARS-CoV-2)-The Contribution of Obesity.
Front Endocrinol (Lausanne). 2020 Oct 6;11:556962. doi: 10.3389/fendo.2020.556962. eCollection 2020.
6
Impacts of Type 2 Diabetes on Disease Severity, Therapeutic Effect, and Mortality of Patients With COVID-19.
J Clin Endocrinol Metab. 2020 Dec 1;105(12). doi: 10.1210/clinem/dgaa535.
7
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study.
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833. doi: 10.1016/S2213-8587(20)30271-0. Epub 2020 Aug 13.
8
COVID-19: immunopathogenesis and Immunotherapeutics.
Signal Transduct Target Ther. 2020 Jul 25;5(1):128. doi: 10.1038/s41392-020-00243-2.
9
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives.
Nat Rev Cardiol. 2020 Sep;17(9):543-558. doi: 10.1038/s41569-020-0413-9. Epub 2020 Jul 20.
10
COVID-19-Associated Stress (Takotsubo) Cardiomyopathy.
Circ Cardiovasc Imaging. 2020 Jul;13(7):e011222. doi: 10.1161/CIRCIMAGING.120.011222. Epub 2020 Jul 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验